Researchers from the University of Utah Health propose that expanding antibiotic treatment for moderate cholera cases could slow or even stop outbreaks while reducing antibiotic resistance risks. Published in the Bulletin of Mathematical Biology, their modeling study challenges current guidelines, which reserve antibiotics for severe cases.
Current cholera management prioritizes rehydration and limits antibiotics to severe infections to prevent resistance. However, the study reveals that antibiotics shorten the infectious period, from two weeks to just a day, dramatically reducing transmission. By treating moderate cases in slower-spreading outbreaks, fewer people contract cholera overall, lowering cumulative antibiotic use and resistance risks.
Key factors like population density and sanitation infrastructure influence outcomes. In high-transmission settings (e.g., crowded areas with poor sanitation), broader antibiotic use may not offset resistance concerns. But in slower-spreading scenarios, it could halt outbreaks entirely.
“This might be an underused opportunity for cholera control,” says senior author Dr. Lindsay Keegan. Co-author Dr. Sharia Ahmed adds, “Antibiotics stop cholera release into the environment, offering population-level benefits.”
With cholera cases rising globally by a third last year, the findings highlight a potential tool for outbreak response. Further research is needed to refine guidelines, but the study underscores the value of data-driven policy updates for infectious disease management.
Add comment